Roka Bioscience, a Warren, NJ-based of diagnostic tools for industrial markets, raised $20 million in a Series C, according to a press release. Roka’s lead product—an assay for food-safety testing—is expected to hit the market later this year. Roka was formed in 2009 as a spinoff from Gen-Probe (NASDAQ: [[ticker:GPRO]]), a San Diego-based maker of diagnostic tools. All of Roka’s previous investors participated in this round, including Gen-Probe, OrbiMed Advisors, New Enterprise Associates, and TPG Biotech.
Author: Arlene Weintraub
Arlene is an award-winning journalist specializing in life sciences and technology. She was previously a senior health writer based out of the New York City headquarters of BusinessWeek, where she wrote hundreds of articles that explored both the science and business of health. Her freelance pieces have been published in USA Today, US News & World Report, Technology Review, and other media outlets. Arlene has won awards from the New York Press Club, the Association of Health Care Journalists, the Foundation for Biomedical Research, and the American Society of Business Publication Editors. Her book about the anti-aging industry, Selling the Fountain of Youth, was published by Basic Books in September 2010.
View all posts by Arlene Weintraub
